The Medicines Company (MDCO - Analyst Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The uptrend was driven by the firm’s "highly competitive" phase-one data on a cholesterol-lowering drug with bullish views on it 90 days into phase-two testing. This resulted in solid volume with far more shares changing hands than in a normal session. This stock, trading in a volatile price range of $35.10 to $41.50 in the past one-month time frame, showed a pick-up yesterday at $37.95.
None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
The Medicines Company currently carries a Zacks Rank #4 (Sell), while its Earnings ESP is positive.
A better-ranked stock in the same industry is Axovant Sciences Ltd. (AXON - Snapshot Report) , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is MDCO going up? Or down? Predict to see what others think: Up or Down
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>